跳至主要内容
临床试验/NL-OMON56377
NL-OMON56377招募中4 期

SPACe 2 STAR : Safety and pharmacokinetics of antipsychotics in children 2. Studying TDM in An RCT - SPACe 2 STAR

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 17(—)

入选标准

  • Age 6 to 18 years
  • AND Documented clinical diagnosis of autism spectrum disorder according to DSM
  • IV or DSM V and comorbid behavioural problems
  • AND To start treatment with either risperidone or aripiprazole

排除标准

  • Diabetes type I or II
  • Congenital or acquired syndrome associated with changes in appetite, body
  • weight or lipid profile (e.g. Prader Willi)
  • Known history of Long QT syndrome (LQTS), cardiovascular disorders
  • (myocardial infarction or ischaemic heart disease, heart failure, or conduction
  • abnormalities), seizure disorder or oesophageal dysmotility
  • Pregnancy
  • Hypersensitivity to the active substance or to any of the excipients

研究者

相似试验